Martyn A. Sharpe

Martyn A. Sharpe, PhD

John S. "Steve" Dunn, Jr. Distinguished Professorship in Brain Tumor Research, Department of Neurosurgery
Research Professor of Neurosurgery, Academic Institute
Associate Research Member, Research Institute
Houston Methodist

Baskin Lab

Martyn A. Sharpe is a classically trained biochemist and bioenergeticist with a strong background in chemistry and the reactions of both reactive oxygen and nitrogen species. He has had more than a decade’s worth of experience in examining the cell proliferation/death mechanisms, and has examined the growth and characteristics of many different cell types including astrocytes, neurons and neuronal/astrocyte co-cultures.

Dr. Sharpe enjoys a large number of collaborations/friendships with scientists worldwide and has published papers with 85 co-authors over the last 15 years. He is often asked to participate in projects where there is an overlap of chemistry/cell physiology; especially in the areas of reactive oxygen/nitrogen species.

Dr. Sharpe switched from classical biochemistry/bioenergetics into related pathologies, especially of the brain, a decade ago following the death of his uncle from glioblastoma multiforme, soon after diagnosis. He has used the knowledge he acquired to develop drugs and drug delivery systems to target gliomas.
In addition to nanosyringes Sharpe & Baskin have been developing prodrugs to target gliomas that are based on their maturation by monoamine oxidase B (MAOB).

Martyn is deeply committed to neuro-oncology and is determined to develop a therapy to treat the 220,000 people, worldwide, who develop gliomas each year.

Description of Research

Dr Sharpe main areas of research have been the following:
-Design, synthesis and testing in vitro and in vivo MAOB activated pro-drugs and retention dyes for the treatment of glioma.
-Development of targeted nanosyringes for chemotherapy
-Examination of the sensitivity of human brain cells, astrocytes and neuron’s, toward organomercury
-Development of assays for identifying specific lesions in DNA

Areas Of Expertise

Nanotechnology Drug design

The leloir cycle in glioblastoma: Galactose scavenging and metabolic remodeling
Sharpe, MA, Ijare, OB, Baskin, DS, Baskin, AM, Baskin, BN & Pichumani, K 2021, , Cancers, vol. 13, no. 8, 1815.

Elevated levels of circulating betahydroxybutyrate in pituitary tumor patients may differentiate prolactinomas from other immunohistochemical subtypes
Ijare, OB, Holan, C, Hebert, J, Sharpe, MA, Baskin, DS & Pichumani, K 2020, , Scientific Reports, vol. 10, no. 1, 1334.

MP-Pt(IV): A MAOB-sensitive mitochondrial-specific prodrug for treating glioblastoma
Raghavan, S, Baskin, DS & Sharpe, MA 2020, , Molecular Cancer Therapeutics, vol. 19, no. 12, pp. 2445-2453.

MP-Pt(IV): A MAOB-sensitive mitochondrial-specific prodrug for treating glioblastoma
Raghavan, S, Baskin, DS & Sharpe, MA 2020, , Molecular Cancer Therapeutics.

A ”clickable” probe for active MGMT in glioblastoma demonstrates two discrete populations of MGMT
Raghavan, S, Baskin, DS & Sharpe, MA 2020, , Cancers, vol. 12, no. 2, 453.

Proton magnetic resonance spectroscopy characterization of Rathke’s cleft cysts (RCCs): Relevance to the differential diagnosis of pituitary adenomas and RCCs
Ijare, OB, Sharpe, MA, Baskin, DS & Pichumani, K 2020, , Cancers, vol. 12, no. 2, 360.

Fibrinogen chains intrinsic to the brain
Golanov, EV, Sharpe, MA, Regnier-Golanov, AS, Del Zoppo, GJ, Baskin, DS & Britz, GW 2019, , Frontiers in Neuroscience, vol. 13, no. MAY, 541.

Metabolism of fructose in B-cells: A 13C NMR spectroscopy based stable isotope tracer study
Ijare, OB, Baskin, DS, Sharpe, MA & Pichumani, K 2018, , Analytical Biochemistry, vol. 552, pp. 110-117.

PAM-OBG: A monoamine oxidase B specific prodrug that inhibits MGMT and generates DNA interstrand crosslinks, potentiating temozolomide and chemoradiation therapy in intracranial glioblastoma
Sharpe, MA, Raghavan, S & Baskin, DS 2018, , Oncotarget, vol. 9, no. 35, pp. 23923-23943.

Transfer of Dyes and Drugs into Cells Using EGFR-Targeted Nanosyringes
Nilewski, LG, Singh, M, Baskin, DS, Tour, JM & Sharpe, MA 2017, , ACS Chemical Neuroscience.

Metabolic sculpting of the mitochondria, cell signaling and the cancer phenotype
Sharpe, MA, Ismail, N & Baskin, DS 2017, , Translational Cancer Research, vol. 6, pp. S182-S188.

Development of EGFR-targeted, drug/dye loaded nanosyringe for selective cellular imaging
Sharpe, M & Baskin, D 2016, . in Society for Neuro-Oncology conference proceedings. vol. 18, DDIS-07, Oxford University Press, suppl 6, pp. vi48.

Successful Treatment of Intracranial Glioblastoma Xenografts With a Monoamine Oxidase B-Activated Pro-Drug
Sharpe, MA, Livingston, AD, Gist, TL, Ghosh, P, Han, J & Baskin, DS 2015, , EBioMedicine, vol. 2, no. 9, pp. 1122-1132.

Design and synthesis of a MAO-B-selectively activated prodrug based on MPTP: a mitochondria-targeting chemotherapeutic agent for treatment of human malignant gliomas
Sharpe, MA, Han, J, Baskin, AM & Baskin, DS 2015, , ChemMedChem, vol. 10, no. 4, pp. 621-628.

Monoamine oxidase B levels are highly expressed in human gliomas and are correlated with the expression of HiF-1a and with transcription factors Sp1 and Sp3
Sharpe, MA & Baskin, DS 2016, , Oncotarget, vol. 7, no. 3, pp. 3379-3393.

Regulation of the pentose phosphate pathway by an androgen receptor-mTOR-mediated mechanism and its role in prostate cancer cell growth
Tsouko, E, Khan, AS, White, MA, Han, JJ, Shi, Y, Merchant, FA, Sharpe, MA, Xin, L & Frigo, D 2014, , Oncogenesis, vol. 3, no. 5, e103.

Baskin, David, S & Sharpe, Martyn, A 2013, , Patent No. CA2887928, IPC No. A61K 31/ 4375 A I.

B-lymphocytes from a population of children with autism spectrum disorder and their unaffected siblings exhibit hypersensitivity to thimerosal
Sharpe, MA, Gist, TL & Baskin, DS 2013, , Journal of Toxicology, vol. 2013, 801517.

Alterations in sensitivity to estrogen, dihydrotestosterone, and xenogens in b-lymphocytes from children with autism spectrum disorder and Their Unaffected Twins/Siblings
Sharpe, MA, Gist, TL & Baskin, DS 2013, , Journal of Toxicology, vol. 2013, 159810.

Antibody-targeted nanovectors for the treatment of brain cancers
Sharpe, MA, Marcano, DC, Berlin, JM, Widmayer, MA, Baskin, DS & Tour, JM 2012, , ACS Nano, vol. 6, no. 4, pp. 3114-3120.